Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
开发针对革兰氏菌和革兰氏菌的保护性单克隆抗体
基本信息
- 批准号:10577803
- 负责人:
- 金额:$ 38.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcinetobacterAdherenceAdhesivesAntibiotic ResistanceAntibioticsBacteriaBacterial AdhesinsBacterial Drug ResistanceBindingBladderBordetella pertussisCathetersCellsCenters for Disease Control and Prevention (U.S.)ClinicalCloningCollaborationsCombating Antibiotic Resistant BacteriaCommunicable DiseasesContractsDevelopmentDrug resistanceDrug resistant Pseudomonas aeruginosaDrug-resistant CampylobacterDrug-resistant Neisseria GonorrhoeaeEnterobacteriaceaeEnterococcusEnzymesEpitopesExcisionExtended-spectrum β-lactamaseFiberFibrinogenFutureGastrointestinal tract structureGenerationsGoalsGram-Negative BacteriaHealthHost Defense MechanismHumanIndwelling CatheterInfectionInterdisciplinary StudyInvadedKidneyKlebsiellaMannoseMediatingMembraneMethodsMicrobial BiofilmsMolecular ChaperonesMolecular MachinesMonoclonal AntibodiesMonoclonal Antibody TherapyMucous MembraneMulti-Drug ResistanceMutationNatureOperonPathway interactionsPersonsPilumPolymersProteinsPublic HealthPumpReportingResistanceResistance developmentSalmonellaSerotypingSiteSurfaceSystemTechniquesTestingTherapeuticTherapeutic Monoclonal AntibodiesTimeTissuesTransmembrane DomainUnited StatesUropathogenic E. coliUsher ProteinsVaccine DesignVirulenceWorkalternative treatmentantibiotic resistant infectionscarbapenem resistancecarbapenem-resistant Enterobacteriaceaecombatdrug resistant pathogenextracellularfluid flowgene conservationhost colonizationhuman tissueinnovationmulti-drug resistant pathogenmultidrug-resistant Pseudomonas aeruginosanon-typhoidal Salmonellapathogenpathogenic bacteriaperiplasmpilus genespolymerizationpressurepreventprogramsresidenceresistance mechanismresistant Shigellasortasesuccesstherapeutic developmenttoolurinary
项目摘要
PROJECT SUMMARY/ ABSTRACT SUMMARY:
Antibiotic resistance is increasingly a threat to human health resulting in difficult to treat infections, with some
multidrug resistant pathogens being resistant to all or most all antibiotics. To combat this growing crisis, this
U19 is taking an integrated approach to the generation and development of therapeutics against key virulence
mechanism of bacteria. Specifically, this CORE will in an integrated approach with Projects 1 and 2, seek to
develop monoclonal antibody (mAb) therapies against different bacterial adhesins that extensive studies have
shown to be critical for the ability of pathogens to bind to and resist removal from host tissues and surfaces.
Uropathogenic E. coli (UPEC) use CUP adhesive pili tipped with adhesin proteins to bind to a variety of human
tissues including the uninflammed bladder, the inflamed bladder, the kidney, urinary catheters and the
gastrointestinal tract (GIT). In addition, Klebsiella expresses a mannose binding FimH adhesin that is critical for
the ability of Klebsiella to cause UTIs. Further, CUP adhesins in Acinetobacter baumanii, CupD and PrpD, as
well as the EbpA adhesin at the tip of the sortase assembled pilus of the Gram-positive Enterococci, bind to
fibrinogen on implanted catheters to promote biofilm formation and catheter-associated UTIs (CAUTIs). In
collaboration with Project 1 this CORE will use state of the art high throughput cloning and selection methods
to generate mAbs against all of these adhesins and evaluate their potential as antibiotic sparing therapeutics.
These mAbs will also elucidate important epitopes for future anti-adhesin vaccine design. Further, all of the
CUP adhesive pili are assembled by homologous systems involving a periplasmic chaperone and and outer
membrane usher. The usher is a five domain assembly platform for CUP pilus polymerization and its
transmembrane domain functions as a pore for extrusion of the assembled fiber. This pore is gated by a plug
domain that only exits the pore when the usher is assembly a pilus fiber. Thus, usher proteins will be targeted
for mAb generation and mAbs will be selected for both their ability to bind and inhibit usher mediated pilus
assembly and/or for the ability to “open” the usher pore in the absence of a growing pilus fiber. Having an open
pore without a pilus fiber will render the bacteria sensitive to antibiotics from our existing arsenal that are not
generally able to cross the Gram-negative outer membrane and thus are not generally efficacious against
Gram-negative pathogens. Targeting of adhesins and their assembly has the advantage that mutations in the
binding pocket of targeted adhesins or in critical assembly sites in the usher to prevent binding of the
therapeutic to its target would likely destroy adhesin function and thus render the pathogen non-virulent. The
mAbs generated have the promise to be a viable alternative for the treatment of antibiotic-resistant infecitons.
Therapeutic mAbs have not yet been fully harnessed for treating infectious diseases, perhaps due to the
historic success of antibiotics. However, with antibiotic resistance on the rise, it is time to apply these
potentially antibiotic-sparing tools to infectious disease.
项目摘要/摘要摘要:
抗生素耐药性日益威胁人类健康,导致难以治疗的感染,一些
对所有或大部分抗生素都有抗药性的多重耐药病原体。为了应对这场日益严重的危机,这
U19正在采取一种综合的方法来产生和开发针对关键毒力的疗法
细菌的机制。具体地说,这一核心将与项目1和2采取综合办法,力求
开发针对不同细菌粘附素的单抗(MAb)疗法,已有广泛研究
被证明对病原体结合到宿主组织和表面并抵抗从宿主组织和表面移除的能力至关重要。
尿路致病性大肠杆菌(UPEC)使用末端带有粘附素蛋白的杯状粘附性菌毛与多种人
组织包括未发炎的膀胱、发炎的膀胱、肾脏、导尿管和
胃肠道(GIT)。此外,克雷伯氏菌还表达一种甘露糖结合的FimH粘附素,这对
克雷伯氏菌引起尿路感染的能力。此外,鲍曼不动杆菌、CupD和PRPD中的CUP粘附素,AS
以及位于革兰氏阳性肠球菌分解酶组装菌毛末端的EBPA粘附素,结合到
植入导管上的纤维蛋白原可促进生物膜的形成和导管相关性尿路感染(CAUTI)。在……里面
与Project 1合作此核心将使用最先进的高通量克隆和选择方法
制备针对所有这些粘附素的单抗,并评估其作为抗生素节省疗法的潜力。
这些单抗还将阐明未来抗粘附素疫苗设计的重要表位。此外,所有的
杯状粘附性菌毛由含有周质伴侣和外膜的同源系统组装而成
膜引导器。引座器是杯状聚合的五个域组装平台,其
跨膜结构域起到挤出组装纤维的孔的作用。这个小孔是用塞子堵住的
只有在引座员组装毛发纤维时才会离开毛孔的区域。因此,USER蛋白将成为目标
对于mAb的产生和mAbb的选择是因为其结合和抑制引导者介导的菌毛的能力
组件和/或能够在没有生长的绒毛纤维的情况下打开引导器毛孔。敞开心扉
没有菌毛纤维的毛孔会使细菌对我们现有军火库中没有的抗生素敏感
通常能够穿过革兰氏阴性外膜,因此通常对
革兰氏阴性病原体。靶向粘附素及其组装的优势是
靶向粘附素的结合口袋或在引座器中的关键组装部位,以防止结合
对其靶标进行治疗可能会破坏粘附素功能,从而使病原体无毒。这个
产生的单抗有望成为治疗抗生素耐药性感染的一种可行的替代方案。
治疗性单抗尚未完全用于治疗传染病,可能是由于
抗生素取得了历史性的成功。然而,随着抗生素耐药性的上升,是时候应用这些
潜在的节省抗生素的工具,以预防传染病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ali Hassan Ellebedy其他文献
Ali Hassan Ellebedy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ali Hassan Ellebedy', 18)}}的其他基金
Programming Long-lasting Immunity to Coronaviruses (PLUTO)
对冠状病毒进行持久免疫编程 (PLUTO)
- 批准号:
10549475 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
开发针对革兰氏菌和革兰氏菌的保护性单克隆抗体
- 批准号:
10162826 - 财政年份:2021
- 资助金额:
$ 38.6万 - 项目类别:
Developing protective monoclonal antibodies against Gram- and Gram+ bacteria
开发针对革兰氏菌和革兰氏菌的保护性单克隆抗体
- 批准号:
10352467 - 财政年份:2021
- 资助金额:
$ 38.6万 - 项目类别:
Programming Durable Immune Responses To Vaccination
规划对疫苗接种的持久免疫反应
- 批准号:
10319526 - 财政年份:2018
- 资助金额:
$ 38.6万 - 项目类别:
Programming Durable Immune Responses To Vaccination
规划对疫苗接种的持久免疫反应
- 批准号:
10539283 - 财政年份:2018
- 资助金额:
$ 38.6万 - 项目类别:
Programming Durable Immune Responses To Vaccination
规划对疫苗接种的持久免疫反应
- 批准号:
10062811 - 财政年份:2018
- 资助金额:
$ 38.6万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 38.6万 - 项目类别:
Fellowship Programs